What the Emerging Research Tells Us — and What It Doesn't — About Genetic Influences on Naltrexone Response, Including Low-Dose Naltrexone (LDN)

Yoon Hang Kim, MD, MPH

Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician

Medical Disclaimer: This article is for educational and informational purposes only and does not constitute medical advice. Pharmacogenomic testing and naltrexone therapy — at any dose — should be discussed with a qualified healthcare provider who can evaluate your individual clinical context. Nothing in this article should be construed as a recommendation to start, stop, or modify any medication.

Introduction

One of the most common questions I hear from clients considering naltrexone — whether at standard doses for alcohol use disorder or at low doses (LDN) for conditions like ME/CFS, fibromyalgia, or autoimmune disease — is: "Why do some people respond dramatically while others barely notice a difference?"

The answer, increasingly, appears to involve genetics. A growing body of research has begun to identify specific gene variants that influence how naltrexone is metabolized, how effectively it engages its receptor targets, and — in one particularly compelling line of inquiry — how it may restore dysfunctional ion channel activity in immune cells.

This article examines the current evidence for four gene families that have been linked to naltrexone response: OPRM1 (the mu-opioid receptor), ADH1B/ADH1C/ALDH2 (alcohol-metabolizing enzymes), TRPM3 (a calcium ion channel implicated in ME/CFS), and AKR1C4 (the primary enzyme responsible for naltrexone metabolism). I will evaluate each claim against the peer-reviewed literature and highlight where the evidence is strong, where it is preliminary, and where popular summaries may overstate the findings.

OPRM1 rs1799971 (Asn40Asp): The Most-Studied — and Most Overstated — Variant

The OPRM1 gene encodes the mu-opioid receptor (μOR), the primary molecular target of naltrexone. The most widely studied variant is rs1799971 (A118G), which produces a non-synonymous amino acid substitution (asparagine to aspartate at position 40).

What the minor 'G' (Asp40) allele actually does to receptor function is, contrary to how it is often summarized, still unsettled. The original 1998 report described a roughly 3-fold increase in binding affinity for the endogenous ligand beta-endorphin — a gain-of-function interpretation. Later work pointed the other way: reduced cell-surface receptor availability, lower receptor mRNA and protein in human post-mortem brain tissue, reduced receptor availability on PET imaging, and decreased expression in a knock-in mouse model. Consumer genomics reports frequently state flatly that the G allele confers 'lower OPRM1 activity.' That is one defensible reading of a contested literature, not an established fact, and the ambiguity matters because the entire rationale for using this variant to predict naltrexone response depends on knowing which direction the receptor is actually shifted.

Several earlier randomized controlled trials suggested that individuals carrying the Asp40 (G) allele might show greater reductions in heavy drinking when treated with naltrexone, particularly in the context of alcohol use disorder (AUD).¹ Some direct-to-consumer genetics platforms have presented this as a relatively settled finding, implying that the 'GG' genotype reliably predicts superior naltrexone response.

However, the most rigorous evidence tells a more nuanced story. A 2020 systematic review and meta-analysis by Hartwell and colleagues, encompassing seven placebo-controlled RCTs, found that the Asn40Asp variant had a nominally significant moderating effect on only one of five alcohol-consumption outcomes — drinks per day — with a small effect size (d = −0.18, p = 0.02).¹ Critically, this finding was not statistically significant after correction for multiple comparisons. The authors concluded that it "remains unclear" whether rs1799971 predicts naltrexone treatment response.¹

Subsequent work by Anton and colleagues (2020) added further complexity. In a randomized trial, OPRM1 G-allele carriers responded better to naltrexone only when they also carried genotypes indicating normal or lower dopamine tone (DAT1 10/10 or COMT val/val); conversely, OPRM1 A homozygotes responded better when they carried higher-dopamine-tone genotypes (DAT1 9-repeat or COMT met carriers).² This gene-gene interaction implies that single-gene predictions are almost certainly oversimplified. It should be noted that the mechanistic interpretation offered in that paper has itself been contested in the published literature, on the grounds that the OPRM1 G allele is generally associated with reduced mu-opioid receptor function rather than enhanced opioid responsiveness.

Clinical takeaway: The OPRM1 rs1799971 variant is real and biologically plausible, but the clinical evidence for using it as a standalone predictor of naltrexone response is weaker than many consumer genomics summaries suggest. All existing research involves full-dose naltrexone (50 mg/day) for AUD; no studies have examined this variant in the context of LDN.

ADH1B, ADH1C, and ALDH2: Alcohol Metabolism Genes and Naltrexone Response

The ADH1B and ADH1C genes encode subunits of alcohol dehydrogenase, the enzyme responsible for the first step of alcohol metabolism (conversion of ethanol to acetaldehyde). The ALDH2 gene encodes aldehyde dehydrogenase, which catalyzes the second step (conversion of toxic acetaldehyde to harmless acetic acid). Variants in these genes are well-established modulators of alcohol consumption patterns and AUD risk, particularly in East Asian populations.

A 2021 clinical trial by Castaldelli-Maia and colleagues at the University of São Paulo examined 101 male clients with AUD treated with naltrexone (50 mg/day) for 12 weeks, stratified by alcohol-metabolizing genotypes.³ The study found that ADH1C*1 (rs698) and ALDH2*2 (rs671) polymorphisms were associated with better treatment response, while the ADH1B*3 (rs2066702) variant was associated with worse outcomes.³

A Note on Accuracy: At least one consumer genomics summary has reported the directionality of the ADH1B finding backwards — stating that the rs2066702 minor allele is associated with a better naltrexone response. The original study found the opposite: ADH1B*3 carriers recorded more drinking days during treatment, indicating a worse outcome.³ A broader caution also applies here: allele lettering for rs698 and rs671 varies between databases depending on which DNA strand is reported, so a report describing a 'C' or 'G' allele may or may not correspond to the star-allele nomenclature (ADH1C*1, ALDH2*2) used in the clinical literature. Anyone reviewing a pharmacogenomic report should verify claims against the primary study or discuss results with a knowledgeable clinician rather than relying on allele letters alone.

Clinical takeaway: The authors deserve credit for applying a Bonferroni correction (significance set at p < 0.0016 across 32 models), and the reported associations did clear that threshold. But one limitation deserves far more weight than it usually receives when this study is cited. In this cohort, the variant genotypes were rare: roughly 44% carried ADH1C*1, but only about 5% carried ADH1B*3 and about 4% carried ALDH2*2.³ In a sample of 101, that means the ADH1B*3 and ALDH2*2 conclusions rest on approximately four to five individuals each. Effect estimates from subgroups that small are extremely unstable regardless of the p-value attached to them. Add that this was a single, male-only trial with no placebo arm, and the appropriate reading is hypothesis-generating at best. As with OPRM1, all of this concerns full-dose naltrexone for AUD, with no LDN-specific data.

TRPM3: The Most Directly Relevant Genetic Connection to LDN

Of the four gene families discussed in this article, TRPM3 offers the most direct mechanistic link to low-dose naltrexone specifically — not merely full-dose naltrexone for alcohol use disorder.

TRPM3 (Transient Receptor Potential Melastatin 3) is a calcium-permeable cation channel expressed in natural killer (NK) cells and involved in pain transduction, thermosensation, and immune defense. A critical observation is that activation of mu-opioid receptors (μOR) directly inhibits TRPM3 channel activity.⁴ Naltrexone, as a μOR antagonist, blocks this inhibition — effectively restoring TRPM3 function.

In 2016, Marshall-Gradisnik and colleagues reported five single nucleotide polymorphisms in the TRPM3 gene associated with ME/CFS in isolated NK cells, including rs6560200 and rs1891301.⁸ This finding warrants an important statistical caveat: the study compared 39 ME/CFS participants with 30 controls and screened 678 SNPs, with the five TRPM3 associations reaching uncorrected p-values between 0.01 and 0.024. At that volume of testing, associations in this range would not be expected to survive correction for multiple comparisons. These are best regarded as preliminary signals requiring independent replication rather than established risk variants.

Separately — and on firmer methodological ground — electrophysiology and calcium-imaging studies by the same research group demonstrated significantly reduced TRPM3 channel function and TRPM3-dependent calcium influx in NK cells from ME/CFS clients, and showed that naltrexone restored this impaired function in vitro.^4,5 It is worth being precise about what these two lines of work do and do not establish jointly: the genotyping study did not measure channel function, and the functional studies did not genotype and stratify their participants. No published study has yet connected a specific TRPM3 genotype to measured channel impairment to clinical LDN response in the same cohort.

A 2021 review further characterized the therapeutic potential: LDN (3.0–5.0 mg/day) may benefit clients with ME/CFS by negating the μOR-mediated inhibition of TRPM3 and restoring calcium-dependent NK cell functions.⁷ A 2024 paper by Löhn and Wirth extended this framework, proposing that TRPM3 dysfunction is not limited to NK cells but may contribute to broader ME/CFS pathophysiology — including small fiber neuropathy, thermoregulatory disruption, and neuroinflammation — and that TRPM3 restoration by naltrexone may explain the moderate clinical efficacy of LDN observed in practice.⁶

Clinical takeaway: This is the most mechanistically compelling line of evidence connecting naltrexone to a genetic target relevant to LDN. The functional work — impaired TRPM3 activity in ME/CFS and its restoration by naltrexone — is the stronger half of the story.^4,5,6,7 The genotype half remains preliminary. Consumer genomics reports sometimes assign specific risk genotypes at rs6560200 or rs1891301; those genotype-level calls are not something I have been able to trace to a primary source demonstrating impaired channel function, and they should not currently be used to predict who will respond to LDN. The honest summary is that TRPM3 is a promising mechanistic target, not yet a validated pharmacogenomic marker.

AKR1C4: Metabolism Matters — How Your Body Processes Naltrexone

Unlike most medications commonly used in integrative medicine, naltrexone is not metabolized through the cytochrome P450 system. Instead, it is reduced primarily by aldo-keto reductase enzymes — particularly AKR1C4 — to its major active metabolite, 6-β-naltrexol. AKR1C4 demonstrates approximately 20-fold higher catalytic efficiency for this reaction than AKR1C2, and roughly 800-fold higher than AKR1C1.^9,11

This has important pharmacogenomic implications. A 2022 study by Stancil and colleagues examining human liver cytosol samples from 158 organ donors (children and adults) found that AKR1C4 genetic variation (specifically the co-occurring S145C/L311V missense mutations) had a greater effect on naltrexone biotransformation than age alone. The combination of AKR1C4 genotype, age, and sex explained 36% of the variability in 6-β-naltrexol formation.⁹

A companion pharmacokinetic study by the same group found that adolescents carrying AKR1C4 variants (rs3829125 and rs17134592) displayed markedly altered naltrexone exposure: 3.2-fold higher area under the curve (AUC), 4-fold higher peak plasma concentration (Cmax), and delayed time to peak levels — compared to wild-type individuals.¹⁰ The AKR1C4 genotype and food intake together accounted for 82% of the variance in naltrexone systemic exposure.¹⁰

Clinical takeaway: This is arguably the most practically relevant genetic finding for LDN prescribers. Because naltrexone is metabolized almost entirely via AKR1C4 rather than CYP450 enzymes, individuals with reduced-function AKR1C4 variants may experience significantly higher naltrexone exposure at any given dose — including low doses. This could contribute to exaggerated side effects at typical LDN starting doses (e.g., vivid dreams, sleep disruption, nausea) or, conversely, enhanced therapeutic effects. Unlike the OPRM1 and ADH/ALDH literature, which studied only full-dose naltrexone for AUD, the AKR1C4 pharmacokinetic data are dose-agnostic and thus directly applicable to LDN.

Putting It Together: What This Means for LDN Practice

The pharmacogenomics of naltrexone — and LDN specifically — is still in its early chapters. Here is an honest summary of where the evidence stands:

OPRM1 (rs1799971): The most-studied variant, but clinically inconclusive. The largest meta-analysis found the evidence "unclear," and even the underlying direction of the variant's effect on receptor function remains disputed. All data are from full-dose AUD treatment.^1,2

ADH1B/ADH1C/ALDH2: One small (N = 101), male-only, uncontrolled trial, in which the ADH1B*3 and ALDH2*2 findings rest on roughly four to five carriers each. At least one consumer summary reverses the ADH1B direction. No demonstrated LDN relevance.³

TRPM3: Strong mechanistic evidence that TRPM3 dysfunction occurs in ME/CFS and that naltrexone restores TRPM3 function in vitro — this connects directly to LDN's proposed mechanism. The associated SNP data (rs6560200, rs1891301, and others) are far weaker, coming from a small study with a substantial multiple-comparisons burden. Mechanism promising; genotype markers not yet validated.^4,5,6,7,8

AKR1C4: Robust pharmacokinetic evidence that genetic variation dramatically alters naltrexone metabolism and systemic exposure. Directly applicable to LDN dosing. Clinicians should consider AKR1C4 status as a potential contributor to the wide variability in LDN tolerability and response.^9,10,11

The Broader Perspective

It is important for clients to understand that pharmacogenomic testing in this space is not yet ready for routine clinical decision-making about LDN. Most of the existing data come from full-dose naltrexone studies in alcohol use disorder — a fundamentally different clinical context from using 1.5–4.5 mg of naltrexone for chronic pain, ME/CFS, MCAS, or autoimmune conditions. The mechanisms by which LDN exerts its therapeutic effects (transient opioid receptor blockade, glial cell modulation, endorphin upregulation, TRPM3 restoration) are distinct from the sustained opioid antagonism of 50 mg naltrexone.

That said, the TRPM3 and AKR1C4 data are genuinely exciting because they speak directly to LDN's unique pharmacology. As these research lines mature, we may eventually have clinically actionable genetic panels that help individualize LDN dosing and predict which clients are most likely to benefit. We are not there yet — but we are closer than we were five years ago.

References

1. Hartwell EE, Feinn R, Morris PE, et al. Systematic review and meta-analysis of the moderating effect of rs1799971 in OPRM1, the mu-opioid receptor gene, on response to naltrexone treatment of alcohol use disorder. Addiction. 2020;115(8):1426-1437. doi:10.1111/add.14975

2. Anton RF, Voronin KE, Book SW, Latham PK, Randall PK, Glen WB, Hoffman M, Schacht JP. Opioid and dopamine genes interact to predict naltrexone response in a randomized alcohol use disorder clinical trial. Alcohol Clin Exp Res. 2020;44(10):2084-2096. doi:10.1111/acer.14431

3. Castaldelli-Maia JM, Malbergier A, de Oliveira ABP, et al. Exploring the role of alcohol metabolizing genotypes in a 12-week clinical trial of naltrexone for alcohol use disorder. Biomolecules. 2021;11(10):1495. doi:10.3390/biom11101495

4. Cabanas H, Muraki K, Staines D, Marshall-Gradisnik S. Naltrexone restores impaired transient receptor potential melastatin 3 ion channel function in natural killer cells from myalgic encephalomyelitis/chronic fatigue syndrome patients. Front Immunol. 2019;10:2545. doi:10.3389/fimmu.2019.02545

5. Eaton-Fitch N, Du Preez S, Cabanas H, Muraki K, Staines D, Marshall-Gradisnik S. Impaired TRPM3-dependent calcium influx and restoration using naltrexone in natural killer cells of myalgic encephalomyelitis/chronic fatigue syndrome patients. J Transl Med. 2022;20(1):94. doi:10.1186/s12967-022-03297-8

6. Löhn M, Wirth KJ. Potential pathophysiological role of the ion channel TRPM3 in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and the therapeutic effect of low-dose naltrexone. J Transl Med. 2024;22(1):630. doi:10.1186/s12967-024-05412-3

7. Cabanas H, Muraki K, Eaton-Fitch N, Staines DR, Marshall-Gradisnik S. Potential therapeutic benefit of low dose naltrexone in myalgic encephalomyelitis/chronic fatigue syndrome: role of transient receptor potential melastatin 3 ion channels in pathophysiology and treatment. Front Immunol. 2021;12:687806. doi:10.3389/fimmu.2021.687806

8. Marshall-Gradisnik S, Huth T, Chacko A, et al. Natural killer cells and single nucleotide polymorphisms of specific ion channels and receptor genes in myalgic encephalomyelitis/chronic fatigue syndrome. Appl Clin Genet. 2016;9:39-47. doi:10.2147/TACG.S99405

9. Stancil SL, Nolte W, Pearce RE, Staggs VS, Leeder JS. The impact of age and genetics on naltrexone biotransformation. Drug Metab Dispos. 2022;50(2):168-173. doi:10.1124/dmd.121.000646

10. Stancil SL, Voss M, Nolte W, Tumberger J, Adelman W, Abdel-Rahman S. Effects of genotype and food on naltrexone exposure in adolescents. Clin Transl Sci. 2022;15(11):2732-2743. doi:10.1111/cts.13399

11. Breyer-Pfaff U, Nill K. Carbonyl reduction of naltrexone and dolasetron by oxidoreductases isolated from human liver cytosol. J Pharm Pharmacol. 2004;56(12):1601-1606. doi:10.1211/0022357045020

About Dr. Kim

Dr. Yoon Hang "John" Kim is board-certified in Preventive Medicine and Integrative & Holistic Medicine with over 20 years of clinical experience. He completed integrative medicine fellowship training at the University of Arizona under Dr. Andrew Weil and holds additional certifications in medical acupuncture (UCLA) and functional medicine (IFM Scholar). He specializes in LDN, autoimmune conditions, chronic pain, integrative oncology, fibromyalgia, CFS/ME, MCAS, and mold toxicity. Dr. Kim is the author of 3 books — including the LDN Primer and a clinical LDN textbook — and over 20 peer-reviewed articles.

Professional: www.yoonhangkim.com  |  Clinical: www.directintegrativecare.com